Non-invasive prenatal screening (NIPS) offers high-risk obstetric patients a noninvasive way to determine the risk of birth defects through a blood test. This is achieved by measuring traces of fetal DNA found in maternal blood; the test can detect fetal aneuploidies with excellent accuracy across all common fetal chromosomal abnormalities. Provides invaluable insight to patient for taking informed decisions with regard to electing CVS or amniocentesis (invasive) versus Non-invasive prenatal screening (NIPS) method.•
It is used as 1st tier screening test for high-risk pregnancy or 2nd tier screening for general and high-risk pregnancy
Higher positive predictive value (PPV) than MSS, NT, or a combination of both.•
Non-invasive prenatal screening (NIPS) can be performed from as early as 10 weeks gestation.•
Whole genome massively parallel shotgun sequencing (MPSS).•
Binary positive/negative result for core trisomies (T21, T18, T13).
Non-invasive prenatal screening test (NIPT)